ArticlePloS one2014
Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04816968 (TAID Study - A Prospective Interventional Trial on Antibiotics Continuous Infusion at Home), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TAID Study - A Prospective Interventional Trial on Antibiotics Continuous Infusion at Home
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Mortality of continuous infusion versus intermittent bolus of meropenem: a systematic review and meta-analysis of randomized controlled trials.Frontiers in microbiology · 2024Pooled it
- Systematic review of room temperature stability of key beta-lactam antibiotics for extended infusions in inpatient settings.European journal of hospital pharmacy : science and practice · 2023Pooled it
- The MOBILISE study: utilisation of ambulatory pumps in the inpatient setting to administer continuous antibiotic infusions-a randomised controlled trial.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Trial
- Rising Carbapenem MICs and Clinical Dose Optimization: Bridging Resistance Surveillance and Pharmacokinetic/Pharmacodynamic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Effectiveness, Tolerance, and Safety of Meropenem in a Pediatric Outpatient Parenteral Antimicrobial Therapy Program.The Canadian journal of hospital pharmacy · 2025Article
- Container closure integrity testing and process validation of closed system transfer devices for aseptic reconstitution of drug vials connected to fluid bags.European journal of hospital pharmacy : science and practice · 2024Article
- Stability of meropenem in portable elastomeric infusion devices: which protocol should be implemented in clinical practice?Microbiology spectrum · 2024Article
- Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation study.PloS one · 2024Article
- Ampicillin Stability in a Portable Elastomeric Infusion Pump: A Step Forward in Outpatient Parenteral Antimicrobial Therapy.Pharmaceutics · 2023Article
- Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Successful Integration of Clinical Pharmacists in an OPAT Program: A Real-Life Multidisciplinary Circuit.Antibiotics (Basel, Switzerland) · 2022Review
- Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy.JAC-antimicrobial resistance · 2021Article
- The Role of Non-Enzymatic Degradation of Meropenem-Insights from the Bottle to the Body.Antibiotics (Basel, Switzerland) · 2021Article
- Continuous infusion of antibiotics using elastomeric pumps in the hospital at home setting.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021Observational
- Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting.European journal of hospital pharmacy : science and practice · 2020Article
- Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study.European journal of hospital pharmacy : science and practice · 2020Article
- Suitability of Amoxicillin-Clavulanic Acid for Administration via Prolonged Infusion.Drug design, development and therapy · 2020Article
- Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.JAC-antimicrobial resistance · 2019Review
- Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion.Hospital pharmacy · 2019Article
- An investigation of the stability of meropenem in elastomeric infusion devices.Drug design, development and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesConcerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services.
methodsWe retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1% (2.4 g) or 2% (4.8 g) concentrations at either 'room temperature' or 'cooled' conditions. Infusate aliquots were assayed at different time-points over 24 hours.
resultsForty-one (82%) of 50 patients had clinical improvement or were cured. Adverse patient outcomes including hemato-, hepato- and nephrotoxicity were infrequent. Cooled infusers with 1% meropenem had a mean 24-hour recovery of 90.3%. Recoveries of 1% and 2% meropenem at room temperature and 2% under cooled conditions were 88%, 83% and 87%, respectively. Patients receiving 1% meropenem are likely to receive >95% of the maximum deliverable dose (MDD) over a 24-hour period whilst patients receiving 2% meropenem should receive 93% and 87% of the MDD under cooled and room temperature conditions, respectively.
conclusionsMeropenem infusers are likely to deliver ∼95% MDD and maintain effective plasma concentrations throughout the dosing period. These data reflect our local favourable clinical experience with meropenem CIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.